Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 27	OCT 07	Multiple databases enhanced for more flexible patent number searching

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:48:57 ON 14 OCT 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:49:07 ON 14 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 OCT 2008  HIGHEST RN 1060442-20-7
DICTIONARY FILE UPDATES:  12 OCT 2008  HIGHEST RN 1060442-20-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\11664190s4.str
```



```
chain nodes :
1  3  4  5  8  9  10  11  13  16  19
ring nodes :
2  6  7
chain bonds :
1-2  1-16  3-4  3-13  4-5  5-11  8-10  8-9  8-19  13-19  16-19
ring bonds :
2-6  2-7  6-7
exact/norm bonds :
2-6  2-7  3-4  4-5  5-11  6-7  8-10  8-9  8-19  13-19  16-19
exact bonds :
1-2  1-16  3-13


G1:C,N

Match level :
1:CLASS  2:Atom  3:CLASS  4:CLASS  5:CLASS  6:Atom  7:Atom  8:CLASS  9:CLASS
10:CLASS  11:CLASS  13:CLASS  16:CLASS  19:Atom
Element Count :
Node 19: Limited
    C,C5
    N,N1




L1      STRUCTURE UPLOADED

=> s l1 sss sam
SAMPLE SEARCH INITIATED 15:49:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     6057 TO ITERATE

 33.0% PROCESSED     2000 ITERATIONS                                 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       116474 TO   125806
PROJECTED ANSWERS:           23764 TO    28082

L2           50 SEA SSS SAM L1
```

```
=> s l1 sss full
FULL SEARCH INITIATED 15:49:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   120165 TO ITERATE

100.0% PROCESSED   120165 ITERATIONS                          27162 ANSWERS
SEARCH TIME: 00.00.01

L3        27162 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.36     178.57

FILE 'CAPLUS' ENTERED AT 15:49:44 ON 14 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Oct 2008  VOL 149 ISS 16
FILE LAST UPDATED: 12 Oct 2008  (20081012/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4        3039 L3

=> s l3 and glycine
          3039 L3
        170626 GLYCINE
          2668 GLYCINES
        171897 GLYCINE
                 (GLYCINE OR GLYCINES)
L5         170 L3 AND GLYCINE

=> s l3 and "glycine transporter"
          3039 L3
        170626 "GLYCINE"
          2668 "GLYCINES"
        171897 "GLYCINE"
                 ("GLYCINE" OR "GLYCINES")
         58070 "TRANSPORTER"
         26829 "TRANSPORTERS"
         67556 "TRANSPORTER"
```

```
                ("TRANSPORTER" OR "TRANSPORTERS")
            517 "GLYCINE TRANSPORTER"
                ("GLYCINE"(W)"TRANSPORTER")
L6            9 L3 AND "GLYCINE TRANSPORTER"

=> d ibib abs hitstr 9

L6   ANSWER 9 OF 9  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:451128  CAPLUS
DOCUMENT NUMBER:          142:476263
TITLE:                    4-Phenylpiperidine derivative glycine
                          transporter inhibitors for the treatment of
                          neurological and psychiatric disorders
INVENTOR(S):              Lindsley, Craig W.; Wisnoski, David D.; Zhao, Zhijian
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 76 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2005046601         A2    20050526    WO 2004-US37359          20041110
     WO 2005046601         A3    20050818
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
             SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     AU 2004289290         A1    20050526    AU 2004-289290           20041110
     CA 2544981            A1    20050526    CA 2004-2544981          20041110
     EP 1684759            A2    20060802    EP 2004-810610           20041110
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
     CN 1878551            A     20061213    CN 2004-80033295         20041110
     JP 2007512251         T     20070517    JP 2006-539749           20041110
     IN 2006DN01895        A     20070615    IN 2006-DN1895           20060407
     US 20070105902        A1    20070510    US 2006-579261           20060511
PRIORITY APPLN. INFO.:                        US 2003-519348P     P  20031112
                                              WO 2004-US37359     W  20041110
OTHER SOURCE(S):          MARPAT 142:476263
AB   The invention discloses 4-phenylpiperidine derivs. that inhibit the
     glycine transporter GlyT1 and which are useful in the
     treatment of neurol. and psychiatric disorders associated with glycinergic or
     glutamatergic neurotransmission dysfunction and diseases in which the
     glycine transporter GlyT1 is involved.  Compound preparation is
     described.
IT   852029-09-5P 852029-10-8P 852029-11-9P
     852029-12-0P 852029-13-1P 852029-14-2P
     852029-15-3P 852029-16-4P 852029-17-5P
     852029-18-6P 852029-19-7P 852029-20-0P
     852029-21-1P 852029-22-2P 852029-23-3P
     852029-24-4P 852029-25-5P 852029-26-6P
     852029-27-7P 852029-28-8P 852029-29-9P
```

852029-30-2P 852029-31-3P 852029-32-4P
852029-33-5P 852029-35-7P 852029-36-8P
852029-37-9P 852029-38-0P 852029-39-1P
852029-40-4P 852029-49-3P 852029-53-9P
852029-54-0P 852029-55-1P 852029-56-2P
852029-63-1P 852029-64-2P 852029-65-3P
852029-66-4P 852029-67-5P 852029-68-6P
852029-69-7P 852029-73-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylpiperidine derivative glycine transporter inhibitors for treatment of neurol. and psychiatric disorders)

RN 852029-09-5 CAPLUS
CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-10-8 CAPLUS
CN Butanamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-11-9 CAPLUS
CN Benzamide, 4-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-12-0 CAPLUS
CN Benzamide, 2-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-13-1 CAPLUS
CN Benzamide, 2-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-14-2 CAPLUS
CN Cyclopropanecarboxamide, 2-phenyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 852029-15-3 CAPLUS
CN Cyclohexanecarboxamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-16-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-17-5 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-18-6 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-19-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-20-0 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-21-1 CAPLUS
CN Benzamide, 2,3-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-22-2 CAPLUS
CN Benzamide, 3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-23-3 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-24-4 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-25-5 CAPLUS
CN Benzamide, 2-(difluoromethoxy)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-26-6 CAPLUS
CN Benzamide, 2,5-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-27-7 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-28-8 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-29-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylthio)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-30-2 CAPLUS
CN 3-Pyridinecarboxamide, 2,6-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-31-3 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-32-4 CAPLUS
CN Benzamide, 2-chloro-6-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-33-5 CAPLUS
CN Benzamide, 2-bromo-3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-35-7 CAPLUS
CN Benzamide, 2-bromo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-36-8 CAPLUS
CN Benzamide, 2-amino-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-37-9 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-38-0 CAPLUS
CN Benzamide, 2-amino-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-39-1 CAPLUS
CN Benzamide, 2-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-40-4 CAPLUS
CN Benzamide, 2-fluoro-6-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-49-3 CAPLUS
CN Benzamide, 2-fluoro-6-hydroxy-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-53-9 CAPLUS
CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-54-0 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-55-1 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-56-2 CAPLUS
CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(methylthio)- (CA INDEX NAME)



RN 852029-63-1 CAPLUS
CN Benzamide, N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-64-2 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-65-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-66-4 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-67-5 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-68-6 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-[[(2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)



RN 852029-69-7 CAPLUS
CN Benzamide, 2-[[[2-(diethylamino)ethyl]amino]methyl]-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 4-iodo-2-(methylamino)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



=> s l5 and nmda
30199 NMDA

```
             2 NMDAS
         30199 NMDA
                 (NMDA OR NMDAS)
L7           2 L5 AND NMDA

=> d ibib abs hitsrt 2
'HITSRT' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
```

information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d ibib abs hitstr 2

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:278950 CAPLUS
DOCUMENT NUMBER: 126:251169
ORIGINAL REFERENCE NO.: 126:48567a,48570a
TITLE: Preparation of novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives as AMPA, kainate and/or glycine binding sites of the NMDA receptor ligands
INVENTOR(S): Acklin, Pierre; Allgeier, Hans; Auberson, Yves; Biollaz, Michel; Moretti, Robert; Ofner, Silvio; Veenstra, Siem Jacob
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Acklin, Pierre; Allgeier, Hans; Auberson, Yves; Biollaz, Michel; Moretti, Robert; Ofner, Silvio; Veenstra, Siem Jacob
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9708155	A1	19970306	WO 1996-EP3644	19960819
W: AL, AU, BB, BG, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2227851	A1	19970306	CA 1996-2227851	19960819
AU 9668742	A	19970319	AU 1996-68742	19960819
AU 705871	B2	19990603		
EP 853617	A1	19980722	EP 1996-929275	19960819
EP 853617	B1	20040303		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
CN 1193968	A	19980923	CN 1996-196581	19960819
HU 9801676	A2	19990329	HU 1998-1676	19960819
HU 9801676	A3	19990428		
JP 11511444	T	19991005	JP 1997-509801	19960819
JP 3159711	B2	20010423		
IL 122987	A	20010808	IL 1996-122987	19960819
AT 260902	T	20040315	AT 1996-929275	19960819
PT 853617	T	20040630	PT 1996-929275	19960819
ES 2217324	T3	20041101	ES 1996-929275	19960819
PL 189637	B1	20050930	PL 1996-324992	19960819
TW 438782	B	20010607	TW 1996-85110230	19960822
IN 1996MA01489	A	20071026	IN 1996-MA1489	19960823
ZA 9607322	A	19970228	ZA 1996-7322	19960829
NO 9800814	A	19980421	NO 1998-814	19980226
NO 310236	B1	20010611		

US 6080743	A	20000627	US 1998-29525		19980227
HK 1010196	A1	20050121	HK 1998-111287		19981016
PRIORITY APPLN. INFO.:			CH 1995-2479	A	19950831
			CH 1995-2734	A	19950927
			CH 1995-2747	A	19950928
			CH 1996-1213	A	19960510
			CH 1996-1630	A	19960628
			CH 1996-1214	A	19960510
			WO 1996-EP3644	W	19960819

OTHER SOURCE(S): MARPAT 126:251169

GI



I



II

AB The title compds. [I; one of R1 and R2 = R5 and the other = CH(R6)-alk-R7, alk-CH(R6)R7, etc. (wherein R5 = R3, R4; R6 = unsubstituted or lower alkylated and/or lower alkanoylated amino; R7 = H, an aliphatic, cycloaliph., heterocycloaliph. radical, etc.); R3, R4 = H, lower alkyl, halo, etc.], useful in the preparation of a medicament for the treatment of pathol. conditions that are responsive to blocking of AMPA, kainate and/or glycine binding sites of the NMDA receptor, were prepared and formulated. Thus, reaction of 7-bromo-5-bromomethyl-2,3-dimethoxyquinoxaline with glycine tert-Bu ester hydrochloride in the presence of Et3N in MeCN followed by deesterification afforded the title compound II.HBr. Compds. I are effective at 10-500 mg/day when administered orally to 75 kg patient.

IT 188694-97-5P 188694-98-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivs. as AMPA, kainate and/or glycine binding sites of the NMDA receptor ligands)

RN 188694-97-5 CAPLUS

CN Acetamide, N-[[1-[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]-4-piperidinyl]methyl]-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 188694-98-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[1-[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]-4-piperidinyl]methyl]-, hydrobromide (1:2) (CA INDEX NAME)



● 2 HBr

=> d ibib abs hitstr 1

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1093266 CAPLUS
DOCUMENT NUMBER: 145:432223
TITLE: Method of treating schizophrenia prodrome
INVENTOR(S): Woods, Scott W.
PATENT ASSIGNEE(S): Yale University, USA
SOURCE: PCT Int. Appl., 64pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110724	A2	20061019	WO 2006-US13444	20060411
WO 2006110724	A3	20070322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006235400	A1	20061019	AU 2006-235400	20060411
CA 2602626	A1	20061019	CA 2006-2602626	20060411
EP 1871165	A2	20080102	EP 2006-740849	20060411
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008535864	T	20080904	JP 2008-505637	20060411
PRIORITY APPLN. INFO.:			US 2005-670600P P	20050411
			WO 2006-US13444 W	20060411

OTHER SOURCE(S): MARPAT 145:432223

AB The present invention relates to a method of treating schizophrenia prodrome in human subjects using a NMDA glycine site agonist, a glycine transporter-1 inhibitor or mixts. thereof, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.

IT 852029-09-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treating schizophrenia prodrome with NMDA glycine agonist and glycine transporter-1 inhibitor)

RN 852029-09-5 CAPLUS

CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



=> s l5 and schizophrenia
20172 SCHIZOPHRENIA
39 SCHIZOPHRENIAS

```
         20176 SCHIZOPHRENIA
                 (SCHIZOPHRENIA OR SCHIZOPHRENIAS)
L8           9 L5 AND SCHIZOPHRENIA

=> d ibib abs hitstr 9

L8   ANSWER 9 OF 9  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:451128  CAPLUS
DOCUMENT NUMBER:          142:476263
TITLE:                    4-Phenylpiperidine derivative glycine
                          transporter inhibitors for the treatment of
                          neurological and psychiatric disorders
INVENTOR(S):              Lindsley, Craig W.; Wisnoski, David D.; Zhao, Zhijian
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 76 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2005046601         A2    20050526    WO 2004-US37359          20041110
     WO 2005046601         A3    20050818
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
             SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     AU 2004289290         A1    20050526    AU 2004-289290           20041110
     CA 2544981            A1    20050526    CA 2004-2544981          20041110
     EP 1684759            A2    20060802    EP 2004-810610           20041110
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
     CN 1878551            A     20061213    CN 2004-80033295         20041110
     JP 2007512251         T     20070517    JP 2006-539749           20041110
     IN 2006DN01895        A     20070615    IN 2006-DN1895           20060407
     US 20070105902        A1    20070510    US 2006-579261           20060511
PRIORITY APPLN. INFO.:                       US 2003-519348P     P    20031112
                                             WO 2004-US37359     W    20041110
OTHER SOURCE(S):          MARPAT 142:476263
AB   The invention discloses 4-phenylpiperidine derivs. that inhibit the
     glycine transporter GlyT1 and which are useful in the treatment of
     neurol. and psychiatric disorders associated with glycinergic or
     glutamatergic neurotransmission dysfunction and diseases in which the
     glycine transporter GlyT1 is involved.  Compound preparation is
     described.
IT   852029-09-5P 852029-10-8P 852029-11-9P
     852029-12-0P 852029-13-1P 852029-14-2P
     852029-15-3P 852029-16-4P 852029-17-5P
     852029-18-6P 852029-19-7P 852029-20-0P
     852029-21-1P 852029-22-2P 852029-23-3P
     852029-24-4P 852029-25-5P 852029-26-6P
     852029-27-7P 852029-28-8P 852029-29-9P
     852029-30-2P 852029-31-3P 852029-32-4P
```

852029-33-5P 852029-35-7P 852029-36-8P
852029-37-9P 852029-38-0P 852029-39-1P
852029-40-4P 852029-49-3P 852029-53-9P
852029-54-0P 852029-55-1P 852029-56-2P
852029-63-1P 852029-64-2P 852029-65-3P
852029-66-4P 852029-67-5P 852029-68-6P
852029-69-7P 852029-73-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylpiperidine derivative glycine transporter inhibitors for treatment of neurol. and psychiatric disorders)

RN 852029-09-5 CAPLUS
CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-10-8 CAPLUS
CN Butanamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-11-9 CAPLUS
CN Benzamide, 4-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-12-0 CAPLUS
CN Benzamide, 2-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-13-1 CAPLUS
CN Benzamide, 2-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-14-2 CAPLUS
CN Cyclopropanecarboxamide, 2-phenyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 852029-15-3 CAPLUS
CN Cyclohexanecarboxamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-16-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-17-5 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-18-6 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-19-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-20-0 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-21-1 CAPLUS
CN Benzamide, 2,3-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-22-2 CAPLUS
CN Benzamide, 3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-23-3 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-24-4 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-25-5 CAPLUS
CN Benzamide, 2-(difluoromethoxy)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-26-6 CAPLUS
CN Benzamide, 2,5-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-27-7 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-28-8 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-29-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylthio)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-30-2 CAPLUS
CN 3-Pyridinecarboxamide, 2,6-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-31-3 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-32-4 CAPLUS
CN Benzamide, 2-chloro-6-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-33-5 CAPLUS
CN Benzamide, 2-bromo-3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-35-7 CAPLUS
CN Benzamide, 2-bromo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-36-8 CAPLUS
CN Benzamide, 2-amino-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-37-9 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-38-0 CAPLUS
CN Benzamide, 2-amino-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-39-1 CAPLUS
CN Benzamide, 2-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-40-4 CAPLUS
CN Benzamide, 2-fluoro-6-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-49-3 CAPLUS
CN Benzamide, 2-fluoro-6-hydroxy-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-53-9 CAPLUS
CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-54-0 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-55-1 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-56-2 CAPLUS
CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(methylthio)- (CA INDEX NAME)



RN 852029-63-1 CAPLUS
CN Benzamide, N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-64-2 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-65-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-66-4 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-67-5 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-68-6 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-[[(2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)



RN 852029-69-7 CAPLUS
CN Benzamide, 2-[[[2-(diethylamino)ethyl]amino]methyl]-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 4-iodo-2-(methylamino)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	37.20	215.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

FILE 'REGISTRY' ENTERED AT 15:55:45 ON 14 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 OCT 2008 HIGHEST RN 1060442-20-7
DICTIONARY FILE UPDATES: 12 OCT 2008 HIGHEST RN 1060442-20-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\11664190s4.str



chain nodes :
1 3 4 5 8 9 10 11 13 16 19
ring nodes :
2 6 7
chain bonds :
1-2 1-16 3-4 3-13 4-5 5-11 8-10 8-9 8-19 13-19 16-19
ring bonds :
2-6 2-7 6-7
exact/norm bonds :
2-6 2-7 3-4 4-5 5-11 6-7 8-10 8-9 8-19 13-19 16-19
exact bonds :
1-2 1-16 3-13

```
G1:C,N

Match level :
1:CLASS  2:Atom  3:CLASS  4:CLASS  5:CLASS  6:Atom  7:Atom  8:CLASS  9:CLASS
10:CLASS  11:CLASS  13:CLASS  16:CLASS  19:Atom
Element Count :
Node 19: Limited
    C,C5
    N,N1




L9      STRUCTURE UPLOADED

=> s l9 sss sam
SAMPLE SEARCH INITIATED 15:57:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   150806 TO ITERATE

  1.3% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      2993175 TO  3039065
PROJECTED ANSWERS:               0 TO        0

L10           0 SEA SSS SAM L9

=> s c5n/rf
L11    3901148 C5N/RF

=> s l9 sub=l11 sam
SAMPLE SUBSET SEARCH INITIATED 15:57:53 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -    68027 TO ITERATE

  2.9% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):           ONLINE  **INCOMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):      1344998 TO  1376082
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):               0 TO        0

L12           0 SEA SUB=L11 SSS SAM L9

=> s c3/rf
L13     641442 C3/RF

=> s l9 sub=l13 sam
SAMPLE SUBSET SEARCH INITIATED 15:58:26 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -     5240 TO ITERATE

 38.2% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 100459 TO 109141
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 0 TO 0

L14 0 SEA SUB=L13 SSS SAM L9

=> s l9 sub=l13 full
FULL SUBSET SEARCH INITIATED 15:58:50 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 104744 TO ITERATE

100.0% PROCESSED 104744 ITERATIONS 36 ANSWERS
SEARCH TIME: 00.00.02

L15 36 SEA SUB=L13 SSS FUL L9

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 190.50 406.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -3.20

FILE 'CAPLUS' ENTERED AT 15:58:56 ON 14 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Oct 2008 VOL 149 ISS 16
FILE LAST UPDATED: 12 Oct 2008 (20081012/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l15
L16 4 L15

=> d ibib abs hitstr 4

L16 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:143108 CAPLUS
DOCUMENT NUMBER: 140:199212
TITLE: Preparation of fused heterocyclic compounds as peptidase inhibitors
INVENTOR(S): Oi, Satoru; Maezaki, Hironobu; Ikedou, Koji

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 247 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014860	A2	20040219	WO 2003-JP10054	20030807
WO 2004014860	A3	20040521		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003254852	A1	20040225	AU 2003-254852	20030807
JP 2004315496	A	20041111	JP 2003-206492	20030807
EP 1527049	A2	20050504	EP 2003-784567	20030807
EP 1527049	B1	20080716		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 401311	T	20080815	AT 2003-784567	20030807
US 20060135530	A1	20060622	US 2005-523531	20050207

PRIORITY APPLN. INFO.:	JP 2002-231950	A	20020808
	JP 2003-51575	A	20030227
	WO 2003-JP10054	W	20030807

OTHER SOURCE(S): MARPAT 140:199212
GI



I

AB Aromatic ring-fused pyridine compds. represented by the formula (I) [wherein ring A is an optionally substituted 5- to 10-membered aromatic ring; R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X and Y are the same or different and each is a bond, O, S, SO, SO2 or NR3 (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); L is a divalent hydrocarbon group], or salts thereof are prepared These compds. show a superior peptidase-inhibitory activity and are useful as prophylactic or therapeutic agents of diabetes, diabetic complications, impaired glucose tolerance, and obesity. For example, (6-chloro-2-isobutyl-4-phenylquinolin-3-yl)methylamine (II) showed IC50 of 1.6 μM against dipeptidyl peptidase IV. A capsule and tablet containing II were formulated.

IT 660450-61-3P, tert-Butyl [[6-hydroxy-2-(cyclopropylmethyl)-4-(4-

methylphenyl)quinolin-3-yl]methyl]carbamate 660450-62-4P,
tert-Butyl [[6-(2-amino-2-oxoethoxy)-2-(cyclopropylmethyl)-4-(4-
methylphenyl)quinolin-3-yl]methyl]carbamate 660450-73-7P
660450-75-9P 660450-77-1P, tert-Butyl
[[6-((1E)-3-amino-3-oxoprop-1-en-1-yl)-2-(cyclopropylmethyl)-4-(4-
methylphenyl)quinolin-3-yl]methyl]carbamate 660450-95-3P,
tert-Butyl [[6-(3-amino-3-oxopropyl)-2-(cyclopropylmethyl)-4-(4-
methylphenyl)quinolin-3-yl]methyl]carbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of aromatic ring-fused pyridine heterocyclic
compds.
as peptidase inhibitors for prophylactic or therapeutic agents of
diabetes, diabetic complications, impaired glucose tolerance, and
obesity)

RN 660450-61-3 CAPLUS
CN Carbamic acid, [[2-(cyclopropylmethyl)-6-hydroxy-4-(4-methylphenyl)-3-
quinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 660450-62-4 CAPLUS
CN Carbamic acid, [[6-(2-amino-2-oxoethoxy)-2-(cyclopropylmethyl)-4-(4-
methylphenyl)-3-quinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)



RN 660450-73-7 CAPLUS
CN 2-Propenoic acid, 3-[2-(cyclopropylmethyl)-3-[[[(1,1-
dimethylethoxy)carbonyl]amino]methyl]-4-(4-methylphenyl)-6-quinolinyl]-,
ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 660450-75-9 CAPLUS
CN 2-Propenoic acid, 3-[2-(cyclopropylmethyl)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-4-(4-methylphenyl)-6-quinolinyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 660450-77-1 CAPLUS
CN Carbamic acid, [[6-[(1E)-3-amino-3-oxo-1-propenyl]-2-(cyclopropylmethyl)-4-(4-methylphenyl)-3-quinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 660450-95-3 CAPLUS
CN Carbamic acid, [[6-(3-amino-3-oxopropyl)-2-(cyclopropylmethyl)-4-(4-

methylphenyl)-3-quinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



=> d ibib abs hitstr 3

L16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:342953 CAPLUS
DOCUMENT NUMBER: 144:369920
TITLE: Cyclopropyl piperidine glycine transporter inhibitors for treatment of neurological and psychiatric disorders
INVENTOR(S): Lindsley, Craig W.; Wisnoski, David D.; Wolkenberg, Scott E.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006039221	A2	20060413	WO 2005-US34301	20050926
WO 2006039221	A3	20060908		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005292323	A1	20060413	AU 2005-292323	20050926
CA 2581582	A1	20060413	CA 2005-2581582	20050926
EP 1797035	A2	20070620	EP 2005-801197	20050926
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101031547	A	20070905	CN 2005-80033117	20050926
JP 2008514705	T	20080508	JP 2007-534679	20050926
BR 2005015954	A	20080812	BR 2005-15954	20050926
IN 2007DN01977	A	20070817	IN 2007-DN1977	20070314

US 20080108663	A1	20080508	US 2007-664190		20070328
MX 200703816	A	20070424	MX 2007-3816		20070329
KR 2007058565	A	20070608	KR 2007-707362		20070330
NO 2007002208	A	20070427	NO 2007-2208		20070427
PRIORITY APPLN. INFO.:			US 2004-614942P	P	20040930
			WO 2005-US34301	W	20050926

OTHER SOURCE(S): MARPAT 144:369920

GI



I

AB The present invention is directed to cyclopropyl piperidine compds. (I; R1 = substituted Ph, substituted heterocycle, (un)substituted C1-8 alkyl, (un)substituted C3-6 cycloalkyl; R2 = (un)substituted C1-6 alkyl, (un)substituted C3-6 cycloalkyl; R3,R4 = H, (un)substituted C1-6 alkyl; A = O, NR5; R5 = H, (un)substituted C1-6 alkyl, (un)substituted C3-6 cycloalkyl, benzyl, phenyl; m = 0, 1) that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

IT 882034-96-0P 882034-97-1P 882034-98-2P
882034-99-3P 882035-00-9P 882035-01-0P
882035-02-1P 882035-03-2P 882035-04-3P
882035-05-4P 882035-06-5P 882035-07-6P
882035-08-7P 882035-09-8P 882035-10-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclopropyl piperidine compds. as glycine transporter inhibitors for treatment of neurol. and psychiatric disorders)

RN 882034-96-0 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(cyclopropylmethyl)-1-(ethylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 882034-97-1 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(cyclopropylmethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 882034-98-2 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(cyclopropylmethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-6-fluoro- (CA INDEX NAME)



RN 882034-99-3 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(cyclopropylmethyl)-1-(ethylsulfonyl)-4-piperidinyl]methyl]-6-fluoro- (CA INDEX NAME)



RN 882035-00-9 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(cyclopropylmethyl)-1-[(2,2,2-trifluoroethyl)sulfonyl]-4-piperidinyl]methyl]-4-fluoro- (CA INDEX NAME)



RN 882035-01-0 CAPLUS
CN Cyclohexanecarboxamide, N-[[4-(cyclopropylmethyl)-1-(ethylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 882035-02-1 CAPLUS
CN Benzamide, N-[[4-(cyclopropylmethyl)-1-(ethylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 882035-03-2 CAPLUS
CN Benzamide, N-[[4-(cyclopropylmethyl)-1-(ethylsulfonyl)-4-piperidinyl]methyl]-2,4-difluoro- (CA INDEX NAME)



RN 882035-04-3 CAPLUS
CN Benzamide, N-[[4-(cyclopropylmethyl)-1-(ethylsulfonyl)-4-piperidinyl]methyl]-2,6-difluoro- (CA INDEX NAME)



RN 882035-05-4 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(cyclopropylmethyl)-1-(ethylsulfonyl)-4-piperidinyl]methyl]-4,6-difluoro- (CA INDEX NAME)



RN 882035-06-5 CAPLUS
CN Benzamide, N-[[4-(cyclopropylmethyl)-1-(ethylsulfonyl)-4-piperidinyl]methyl]-2,3-difluoro- (CA INDEX NAME)



RN 882035-07-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(cyclopropylmethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 882035-08-7 CAPLUS
CN 2-Furancarboxamide, N-[[4-(cyclopropylmethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 882035-09-8 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(cyclopropylmethyl)-1-[(1-methylethyl)sulfonyl]-4-piperidinyl]methyl]-4-fluoro- (CA INDEX NAME)



RN 882035-10-1 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(cyclopropylmethyl)-1-(cyclopropylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      11.86     418.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -1.60      -4.80

STN INTERNATIONAL LOGOFF AT 16:00:05 ON 14 OCT 2008
```